Developer docs
API playgroundTry for free, no card

Search company profiles

Lumos Diagnostics

Full company profile

uuid00006k2

Namestring
Lumos Diagnostics
Legal namestring
Lumos Diagnostics Holdings Ltd
Company typeenum
Public
Founded yearint
2019
Descriptiontext

Lumos Diagnostics Holdings Ltd (ASX:LDX) is a point-of-care diagnostics company headquartered in Melbourne, Australia, with an ISO 13485 certified manufacturing and R&D facility in Carlsbad, California. The company's core proprietary product is FebriDx, a rapid fingerstick blood test that uses a dual-biomarker lateral flow immunoassay combining CRP and MxA to differentiate bacterial from non-bacterial acute respiratory infections at the point of care, with FDA 510(k) clearance and CLIA waiver for patients aged 12–64 and an active pediatric extension study funded by BARDA. Results are available in 10 minutes using an instrument-free disposable test, with optional proprietary camera readers and companion Android/iOS apps that provide cloud connectivity, EMR integration, and data management.

Lumos monetizes through three primary revenue streams: (1) direct product sales of FebriDx via exclusive and non-exclusive distribution partners — PHASE Scientific holds exclusivity in the US under a six-year US$317 million agreement, while Henry Schein, Thermo Fisher Scientific, Amtech/YesGroup (ANZ), and a Baltic distributor handle other geographies; (2) contract development and manufacturing services for external diagnostic partners (assay development, reader platforms, app/cloud services, medical affairs, and quality/regulatory affairs), including commercial agreements with Micro-Pak for the Mold Analyzer system and Aptatek for PheCheck PKU monitoring; and (3) milestone and grant payments, including BARDA non-dilutive funding and distribution partner pre-payments (US$7.5M cumulative from PHASE Scientific). US reimbursement for FebriDx is set at US$41.38 per test under CMS.

The customer base spans urgent care centers, primary care clinics, retail pharmacies, emergency departments, community health settings, and university health services (e.g., WellStreet Urgent Care, Texas A&M). H1 FY26 revenue reached US$6.1M at a 68% gross margin with positive operating cash flow, and FebriDx product revenue doubled year-over-year as the company scaled toward the post-CLIA waiver US commercial launch backed by a fresh US$20M institutional placement.

Short descriptiontext

Lumos Diagnostics (ASX:LDX) is a point-of-care diagnostics company that develops and manufactures FebriDx, a rapid dual-biomarker test differentiating bacterial from viral respiratory infections, and provides contract development and manufacturing services for diagnostic partners globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCarlsbad, United States
HQ citystring
Carlsbad
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
point-of-care diagnostics, rapid diagnostic testing, lateral flow immunoassays, contract manufacturing services, bacterial viral differentiation
Industry3 codes
PRIMARYHLAHAOAA
Infectious Disease POCT (Respiratory, STI, HIV, Sepsis)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Laboratories621511
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
Product category
Point-of-Care Diagnostics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1FebriDx Product Sales
TypeHardware Sales
Description

Direct product revenue from FebriDx sales through distribution partners in US, ANZ, and international markets. FebriDx product revenue doubled to USD 1.7 million in H1 FY26. Reimbursement secured at USD 41.38 per test from CMS.

ca.finance.yahoo.com
2Contract Manufacturing Services
TypeProfessional Services
Description

Lumos provides contract development and manufacturing services for diagnostic products including assay development, readers, manufacturing, medical affairs, and regulatory affairs support. Revenue from Micro-Pak Mold Analyzer manufacturing agreement (initial order US$250,000) and Aptatek PheCheck contract (US$400,000 follow-on contract, US$1.5 million original contract).

ca.finance.yahoo.com
3Milestone Payments
TypeLicensing Royalties
Description

Pre-payments and milestone payments from distribution partners (US$7.5 million total pre-payments from PHASE Scientific including US$5 million after CLIA waiver), BARDA funding (US$6.198 million committed for pediatric study), and regulatory milestone payments.

lumosdiagnostics.com
4Distribution Agreement Revenue
TypeTransaction Fee
Description

Six-year distribution agreement with PHASE Scientific valued at USD 317 million activates following CLIA waiver clearance, providing ongoing product order revenue.

clpmag.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1FebriDx test kit reimbursement rate
ModelUnit PricingBilling cadencePay-as-you-go
Notes

CMS reimbursement rate of USD 41.38 per test for FebriDx point-of-care assay

seekingalpha.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1FebriDx
Description

Rapid point-of-care test that uses a fingerstick blood sample to aid in the differentiation between bacterial infection and non-bacterial etiology

lumosdiagnostics.com
+2 more records
Core offering1 text field

Lumos Diagnostics develops, manufactures and distributes rapid point-of-care diagnostic test products, with its flagship FebriDx test using a fingerstick blood sample to differentiate bacterial from non-bacterial acute respiratory infections via dual biomarker (CRP + MxA) technology. The company also provides fee-based contract development, manufacturing, and support services for diagnostic products — including assay development, proprietary digital reader platforms, companion apps, and medical/quality/regulatory affairs — through its ISO 13485 certified Carlsbad, California facility.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 99% NPV (Negative Predictive Value) for ruling out bacterial infection
+7 more records
Product overview1 text field

Lumos Diagnostics offers a portfolio of proprietary point-of-care diagnostic products and comprehensive contract development and manufacturing services. The core proprietary product is FebriDx, a rapid point-of-care test that differentiates bacterial from viral respiratory infections using dual biomarker technology. The company operates an ISO 13485 certified contract manufacturing and development services business supporting external partners, including assay development, reader platforms (disposable and reusable), app/cloud connectivity solutions, medical affairs, and quality/regulatory affairs services. Services are provided through a co-located manufacturing and R&D facility in Carlsbad, California. The company also has contract manufacturing agreements for products like the Micro-Pak Mold Analyzer and is developing the PheCheck PKU monitoring device with Aptatek Biosciences.

Product and service2 records
1FebriDx
CategoryPoint-of-Care Diagnostic Product
Description

Rapid point-of-care test that uses a fingerstick blood sample to differentiate between bacterial infection and non-bacterial etiology in patients aged 12-64 presenting with acute respiratory infection symptoms. Uses proprietary dual biomarker technology combining CRP and MxA, delivers 99% NPV to rule out bacterial infection with results in 10 minutes. FDA 510(k) cleared with CLIA waiver. Sold to US urgent care and emergency care providers via distribution partners.

2Contract Manufacturing Services
Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierSignificantTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-04-09
Description

Three-year contract manufacturing agreement for Mold Analyzer system, the world's first rapid test cassette to detect 56 mould species. Initial purchase order valued at US$250,000. Validates Lumos' services business by converting four years of contract development into commercial-scale manufacturing.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-27
Description

Exclusive US distribution partner for FebriDx under USD 317 million, 6-year distribution agreement. PHASE Scientific has commercial infrastructure built out for broad deployment following FDA CLIA waiver clearance. Provided US$5 million milestone pre-payment and total pre-payments of US$7.5 million.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2026-01-19
Description

Follow-on contract worth approximately US$400,000 to manage clinical study advancing PheCheck in-home PKU monitoring device toward FDA clearance. Six-month agreement on time-and-materials basis. Subject to FDA clearance, Lumos expects to pursue commercial manufacturing opportunities.

Strategic tierSupportingTypeGTM or Marketing PartnerAnnounced on2025-11-20
Description

Strategic collaboration to accelerate market access for FebriDx in US market.

Strategic tierSupportingTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-09-09
Description

New ANZ distribution agreement with Amtech, part of YesGroup alliance. YesGroup employs over 150 team members and offers more than 25,000 product lines across Australia and New Zealand.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-01
Description

US government agency providing non-dilutive funding of up to US$6.198 million for FebriDx pediatric clinical study. Total milestone payments received to date of US$2.59 million. BARDA funding supports pediatric study across 20 US clinical sites enrolling 500-800 patients.

Strategic tierSupportingTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-08-14
Description

US-based market access consultancy providing strategic and operational services to accelerate patient access to FebriDx. Services include development of strategic collateral, dedicated helpline for coding/coverage inquiries, and field support team for provider adoption support. Program running through December 2026.

Strategic tierSupportingTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-09-25
Description

National contract awarded for FebriDx diagnostic test products.

Strategic tierSupportingTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-09-16
Description

Appointed as US distributor for FebriDx products.

Strategic tierSupportingTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-07-09
Description

Expanded distribution partnership for FebriDx in ANZ and US markets. Henry Schein serves as sub-distributor of Lumos' US commercial partner PHASE Scientific and expanded ANZ distribution.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2023-09-20
Description

Development partnership with Hologic, one of the world's leading diagnostic companies. Lumos achieved first Phase 2 milestone in Hologic agreement.

Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Atomo provides proprietary test cassettes to Lumos for the CLIA-waived FebriDx test as supply partner.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct competitor in rapid point-of-care infectious disease diagnostics (Sofia, Triage, QuickVue) sold into urgent care, primary care, and CLIA-waived settings — directly overlapping with FebriDx's positioning and customer base.

2Abbott Diagnostics
TypeBroad incumbent
Description

Incumbent in rapid diagnostics with BinaxNOW and ID NOW platforms widely deployed across US urgent care and retail clinics; comparable distribution scale and respiratory testing footprint to FebriDx but with a much broader menu and balance sheet.

TypeBroad incumbent
Description

Operator of the BioFire FilmArray respiratory panel — the dominant molecular alternative to rapid antigen/bacterial-vs-viral tests; targets overlapping urgent-care and hospital customers with higher-sensitivity molecular results competing for the same antibiotic-stewardship use cases.

TypeBroad incumbent
Description

Sells the BD Veritor system for rapid immunoassay testing in point-of-care settings, directly comparable to Lumos's FebriDx instrument-free platform; broader portfolio and established distribution into US ambulatory care.

TypeBroad incumbent
Description

Markets the Xpert family of molecular point-of-care tests (including Xpress for CLIA-waived settings); competes with FebriDx for rapid respiratory infection workflows but at higher cost and complexity.

TypeBroad incumbent
Description

Major molecular diagnostics company and a current Lumos development partner; comparable respiratory and women's health diagnostics portfolio with established hospital sales channels overlapping FebriDx's target accounts.

TypeDirect peer
Description

Direct peer and critical supplier to Lumos — designs integrated rapid diagnostic test devices (including the cassette platform used in the CLIA-waived FebriDx); competes in the same integrated POC device category while also being a key input supplier.

TypeDirect peer
Description

Develops and manufactures lateral-flow and molecular diagnostic tests across infectious disease; comparable assay-development and contract-manufacturing capabilities to Lumos's Carlsbad services business and overlapping product portfolio.

TypeDirect peer
Description

Provider of rapid immunoassay diagnostics (OSOM brand) and clinical chemistry reagents; directly comparable lateral-flow POCT portfolio targeting urgent care and physician office labs.

TypeEmerging player
Description

Develops rapid immunoassay tests (RAMP platform) for infectious disease and cardiovascular markers; smaller-scale direct competitor to FebriDx in POC immunoassay respiratory testing.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lumos Diagnostics

Point-of-Care Diagnosticslumosdiagnostics.com

Lumos Diagnostics (ASX:LDX) is a point-of-care diagnostics company that develops and manufactures FebriDx, a rapid dual-biomarker test differentiating bacterial from viral respiratory infections, and provides contract development and manufacturing services for diagnostic partners globally.

What Lumos Diagnostics does

Lumos Diagnostics Holdings Ltd (ASX:LDX) is a point-of-care diagnostics company headquartered in Melbourne, Australia, with an ISO 13485 certified manufacturing and R&D facility in Carlsbad, California. The company's core proprietary product is FebriDx, a rapid fingerstick blood test that uses a dual-biomarker lateral flow immunoassay combining CRP and MxA to differentiate bacterial from non-bacterial acute respiratory infections at the point of care, with FDA 510(k) clearance and CLIA waiver for patients aged 12–64 and an active pediatric extension study funded by BARDA. Results are available in 10 minutes using an instrument-free disposable test, with optional proprietary camera readers and companion Android/iOS apps that provide cloud connectivity, EMR integration, and data management.

Lumos monetizes through three primary revenue streams: (1) direct product sales of FebriDx via exclusive and non-exclusive distribution partners — PHASE Scientific holds exclusivity in the US under a six-year US$317 million agreement, while Henry Schein, Thermo Fisher Scientific, Amtech/YesGroup (ANZ), and a Baltic distributor handle other geographies; (2) contract development and manufacturing services for external diagnostic partners (assay development, reader platforms, app/cloud services, medical affairs, and quality/regulatory affairs), including commercial agreements with Micro-Pak for the Mold Analyzer system and Aptatek for PheCheck PKU monitoring; and (3) milestone and grant payments, including BARDA non-dilutive funding and distribution partner pre-payments (US$7.5M cumulative from PHASE Scientific). US reimbursement for FebriDx is set at US$41.38 per test under CMS.

The customer base spans urgent care centers, primary care clinics, retail pharmacies, emergency departments, community health settings, and university health services (e.g., WellStreet Urgent Care, Texas A&M). H1 FY26 revenue reached US$6.1M at a 68% gross margin with positive operating cash flow, and FebriDx product revenue doubled year-over-year as the company scaled toward the post-CLIA waiver US commercial launch backed by a fresh US$20M institutional placement.

Lumos Diagnostics firmographics

Firmographics
Name
Lumos Diagnostics
Legal name
Lumos Diagnostics Holdings Ltd
Website
https://lumosdiagnostics.com
Company type
Public
Founded year
2019
Operating status
Operating
Headcount range
51–100 employees
Short description
Lumos Diagnostics (ASX:LDX) is a point-of-care diagnostics company that develops and manufactures FebriDx, a rapid dual-biomarker test differentiating bacterial from viral respiratory infections, and provides contract development and manufacturing services for diagnostic partners globally.
Ownership category
akta.pro rank

Lumos Diagnostics industry classification

Industry
Product category
Point-of-Care Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAHAOAA
Infectious Disease POCT (Respiratory, STI, HIV, Sepsis)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)

Keywords

  • Point-of-care diagnostics
  • Rapid diagnostic testing
  • Lateral flow immunoassays
  • Contract manufacturing services
  • Bacterial viral differentiation

Where Lumos Diagnostics is headquartered

Location

Headquarters

HQ city
Carlsbad
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Lumos Diagnostics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. FebriDx Product Sales: Direct product revenue from FebriDx sales through distribution partners in US, ANZ, and international markets. FebriDx product revenue doubled to USD 1.7 million in H1 FY26. Reimbursement secured at USD 41.38 per test from CMS.
  2. Contract Manufacturing Services: Lumos provides contract development and manufacturing services for diagnostic products including assay development, readers, manufacturing, medical affairs, and regulatory affairs support. Revenue from Micro-Pak Mold Analyzer manufacturing agreement (initial order US$250,000) and Aptatek PheCheck contract (US$400,000 follow-on contract, US$1.5 million original contract).
  3. Milestone Payments: Pre-payments and milestone payments from distribution partners (US$7.5 million total pre-payments from PHASE Scientific including US$5 million after CLIA waiver), BARDA funding (US$6.198 million committed for pediatric study), and regulatory milestone payments.
  4. Distribution Agreement Revenue: Six-year distribution agreement with PHASE Scientific valued at USD 317 million activates following CLIA waiver clearance, providing ongoing product order revenue.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goFebriDx test kit reimbursement rate

Go-to-market motion2 records

Distribution channels6 records

Marketing channels5 records

Lumos Diagnostics product offering

Product offering

Core offering

Lumos Diagnostics develops, manufactures and distributes rapid point-of-care diagnostic test products, with its flagship FebriDx test using a fingerstick blood sample to differentiate bacterial from non-bacterial acute respiratory infections via dual biomarker (CRP + MxA) technology. The company also provides fee-based contract development, manufacturing, and support services for diagnostic products — including assay development, proprietary digital reader platforms, companion apps, and medical/quality/regulatory affairs — through its ISO 13485 certified Carlsbad, California facility.

Product overview

Lumos Diagnostics offers a portfolio of proprietary point-of-care diagnostic products and comprehensive contract development and manufacturing services. The core proprietary product is FebriDx, a rapid point-of-care test that differentiates bacterial from viral respiratory infections using dual biomarker technology. The company operates an ISO 13485 certified contract manufacturing and development services business supporting external partners, including assay development, reader platforms (disposable and reusable), app/cloud connectivity solutions, medical affairs, and quality/regulatory affairs services. Services are provided through a co-located manufacturing and R&D facility in Carlsbad, California. The company also has contract manufacturing agreements for products like the Micro-Pak Mold Analyzer and is developing the PheCheck PKU monitoring device with Aptatek Biosciences.

Differentiator

Problem solved

Functional benefit

Brands

  • FebriDx: Rapid point-of-care test that uses a fingerstick blood sample to aid in the differentiation between bacterial infection and non-bacterial etiology
  • Mold Analyzer
  • PheCheck

Products and services

  • FebriDx Rapid point-of-care test that uses a fingerstick blood sample to differentiate between bacterial infection and non-bacterial etiology in patients aged 12-64 presenting with acute respiratory infection symptoms. Uses proprietary dual biomarker technology combining CRP and MxA, delivers 99% NPV to rule out bacterial infection with results in 10 minutes. FDA 510(k) cleared with CLIA waiver. Sold to US urgent care and emergency care providers via distribution partners.
  • Contract Manufacturing Services

Quantifiable outcome

  • 99% NPV (Negative Predictive Value) for ruling out bacterial infection
  • +7 more outcomes

Companies that use Lumos Diagnostics

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Lumos Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Lumos Diagnostics partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered significant, core and supporting.

  • Micro-PaksignificantChannel Partner/ Reseller/ Distributor · 9 April 2026Three-year contract manufacturing agreement for Mold Analyzer system, the world's first rapid test cassette to detect 56 mould species. Initial purchase order valued at US$250,000. Validates Lumos' services business by converting four years of contract development into commercial-scale manufacturing.
  • PHASE ScientificcoreChannel Partner/ Reseller/ Distributor · 27 March 2026Exclusive US distribution partner for FebriDx under USD 317 million, 6-year distribution agreement. PHASE Scientific has commercial infrastructure built out for broad deployment following FDA CLIA waiver clearance. Provided US$5 million milestone pre-payment and total pre-payments of US$7.5 million.
  • Aptatek BiosciencessupportingStrategic or Co-development Partner · 19 January 2026Follow-on contract worth approximately US$400,000 to manage clinical study advancing PheCheck in-home PKU monitoring device toward FDA clearance. Six-month agreement on time-and-materials basis. Subject to FDA clearance, Lumos expects to pursue commercial manufacturing opportunities.
  • AcuityMDsupportingGTM or Marketing Partner · 20 November 2025Strategic collaboration to accelerate market access for FebriDx in US market.
  • Amtech/YesGroupsupportingChannel Partner/ Reseller/ Distributor · 9 September 2025New ANZ distribution agreement with Amtech, part of YesGroup alliance. YesGroup employs over 150 team members and offers more than 25,000 product lines across Australia and New Zealand.
  • BARDA (Biomedical Advanced Research and Development Authority)coreStrategic or Co-development Partner · 1 September 2025US government agency providing non-dilutive funding of up to US$6.198 million for FebriDx pediatric clinical study. Total milestone payments received to date of US$2.59 million. BARDA funding supports pediatric study across 20 US clinical sites enrolling 500-800 patients.
  • PRO-spectussupportingImplementation/ SI/ Consulting Partner · 14 August 2025US-based market access consultancy providing strategic and operational services to accelerate patient access to FebriDx. Services include development of strategic collateral, dedicated helpline for coding/coverage inquiries, and field support team for provider adoption support. Program running through December 2026.
  • MediGroupsupportingChannel Partner/ Reseller/ Distributor · 25 September 2024National contract awarded for FebriDx diagnostic test products.
  • Thermo Fisher ScientificsupportingChannel Partner/ Reseller/ Distributor · 16 September 2024Appointed as US distributor for FebriDx products.
  • Henry ScheinsupportingChannel Partner/ Reseller/ Distributor · 9 July 2024Expanded distribution partnership for FebriDx in ANZ and US markets. Henry Schein serves as sub-distributor of Lumos' US commercial partner PHASE Scientific and expanded ANZ distribution.
  • HologicsupportingStrategic or Co-development Partner · 20 September 2023Development partnership with Hologic, one of the world's leading diagnostic companies. Lumos achieved first Phase 2 milestone in Hologic agreement.
  • Atomo DiagnosticssupportingChannel Partner/ Reseller/ DistributorAtomo provides proprietary test cassettes to Lumos for the CLIA-waived FebriDx test as supply partner.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Lumos Diagnostics competitors and assessment

Company assessment

Direct peers

  • QuidelOrtho: Direct competitor in rapid point-of-care infectious disease diagnostics (Sofia, Triage, QuickVue) sold into urgent care, primary care, and CLIA-waived settings — directly overlapping with FebriDx's positioning and customer base.
  • Atomo Diagnostics: Direct peer and critical supplier to Lumos — designs integrated rapid diagnostic test devices (including the cassette platform used in the CLIA-waived FebriDx); competes in the same integrated POC device category while also being a key input supplier.
  • Meridian Bioscience: Develops and manufactures lateral-flow and molecular diagnostic tests across infectious disease; comparable assay-development and contract-manufacturing capabilities to Lumos's Carlsbad services business and overlapping product portfolio.
  • Sekisui Diagnostics: Provider of rapid immunoassay diagnostics (OSOM brand) and clinical chemistry reagents; directly comparable lateral-flow POCT portfolio targeting urgent care and physician office labs.

Broad incumbents

  • Abbott Diagnostics: Incumbent in rapid diagnostics with BinaxNOW and ID NOW platforms widely deployed across US urgent care and retail clinics; comparable distribution scale and respiratory testing footprint to FebriDx but with a much broader menu and balance sheet.
  • bioMérieux: Operator of the BioFire FilmArray respiratory panel — the dominant molecular alternative to rapid antigen/bacterial-vs-viral tests; targets overlapping urgent-care and hospital customers with higher-sensitivity molecular results competing for the same antibiotic-stewardship use cases.
  • Becton Dickinson (BD): Sells the BD Veritor system for rapid immunoassay testing in point-of-care settings, directly comparable to Lumos's FebriDx instrument-free platform; broader portfolio and established distribution into US ambulatory care.
  • Cepheid (Danaher): Markets the Xpert family of molecular point-of-care tests (including Xpress for CLIA-waived settings); competes with FebriDx for rapid respiratory infection workflows but at higher cost and complexity.
  • Hologic: Major molecular diagnostics company and a current Lumos development partner; comparable respiratory and women's health diagnostics portfolio with established hospital sales channels overlapping FebriDx's target accounts.

Emerging players

  • Response Biomedical: Develops rapid immunoassay tests (RAMP platform) for infectious disease and cardiovascular markers; smaller-scale direct competitor to FebriDx in POC immunoassay respiratory testing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Lumos Diagnostics social profiles

Digital presence

Lumos Diagnostics compliance and trust

Trust signal

Compliance1 record

Lumos Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lumos Diagnostics leadership team

Management profile

Number of profiles

Profiles14 records

Lumos Diagnostics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lumos Diagnostics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lumos Diagnostics

What does Lumos Diagnostics do?

Lumos Diagnostics develops, manufactures and distributes rapid point-of-care diagnostic test products, with its flagship FebriDx test using a fingerstick blood sample to differentiate bacterial from non-bacterial acute respiratory infections via dual biomarker (CRP + MxA) technology. The company also provides fee-based contract development, manufacturing, and support services for diagnostic products — including assay development, proprietary digital reader platforms, companion apps, and medical/quality/regulatory affairs — through its ISO 13485 certified Carlsbad, California facility.

Is Lumos Diagnostics a public or private company?

Lumos Diagnostics is a public company. It is classified as public and is currently operating.

When was Lumos Diagnostics founded?

Lumos Diagnostics was founded in 2019. It employs 51 to 100 people.

Where is Lumos Diagnostics based?

Lumos Diagnostics is headquartered in Carlsbad, United States, in the North America region.

How does Lumos Diagnostics make money?

Four revenue lines are on record. FebriDx Product Sales are the primary driver. The others are contract Manufacturing Services, milestone Payments and distribution Agreement Revenue.

Who are Lumos Diagnostics's main competitors?

Direct peers on record are QuidelOrtho, Atomo Diagnostics, Meridian Bioscience and Sekisui Diagnostics. Broad incumbents are Abbott Diagnostics, bioMérieux, Becton Dickinson (BD), Cepheid (Danaher) and Hologic. Response Biomedical is listed as an emerging player.

Does Lumos Diagnostics have an API?

No public API is recorded for Lumos Diagnostics.

What industry is Lumos Diagnostics in?

Lumos Diagnostics's product category is Point-of-Care Diagnostics. Its primary akta.pro industry code is HLAHAOAA, Infectious Disease POCT (Respiratory, STI, HIV, Sepsis), with a secondary code of HLAGAAAH, Pharmacovigilance, Risk Management & Medical Affairs CROs. Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewLumos Diagnostics Holdings Ltd (LDX) Expands FebriDx to 141 LocationsLumos Diagnostics expanded FebriDx adoption to 141 locations in Ohio, Georgia, and Michigan, up from 44 previously announced. The company anticipates further expansion to all 200+ WellStreet locations in the near future, though no revenue or contract-value estimates were disclosed.Seeking AlphaLumos Diagnostics Holdings Limited (LDXHF) Q1 2027 Earnings Call TranscriptLumos Diagnostics held its Q1 FY27 earnings call on October 26, 2026, with CEO Douglas Ward and CFO Barrie Lambert. The company focused on preparing for the upcoming North American flu season and noted recent board-level changes. The presentation was lodged with the ASX.AInvestLumos Diagnostics - FY26 revenue of US$13.2 mlnNo content on the titled subject is present; the body is a paywall stub with only a headline and subscription prompts.The AustralianLumos Diagnostics lands PHASE Scientific orderLumos Diagnostics has received a purchase order worth US$767,800 from PHASE Scientific for its FebriDx test, which distinguishes between bacterial and viral respiratory infections. This order is part of a six-year distribution agreement and follows a CLIA waiver granted by the US FDA in March 2026. The delivery of the product is expected to continue through October 2026 as Lumos advances its commercialization efforts.MarketScreenerLumos Diagnostics Receives Initial Blood Test Purchase Order Under Distribution Agreement; Shares Up 7%Lumos Diagnostics Holdings Limited received an initial purchase order for blood tests under a distribution agreement, driving shares up 7%. The article provides limited detail beyond the headline announcement, with the body consisting primarily of company profile boilerplate rather than substantive news content. No further details about the distribution agreement partner, order value, or timeline were available in the scraped content.AInvestLumos Diagnostics - receives US$767,800 FebriDx order from Phase ScientificLumos Diagnostics has received a US$767,800 purchase order for its FebriDx® rapid diagnostic test from PHASE Scientific, its exclusive U.S. distribution partner. The order is part of a broader six-year commercial agreement with a total contract value of up to US$317 million and supports PHASE Scientific's efforts to scale FebriDx® commercialization across the U.S. market. The test, which has FDA 510(k) clearance, is currently undergoing a CLIA waiver study expected to complete by August 2026, which would expand the product's addressable market to physician offices and urgent care clinics.Seeking AlphaLumos Diagnostics Holdings Limited (LDXHF) Q4 2026 Earnings Call TranscriptThe article reports on Lumos Diagnostics Holdings Limited's Q4 2026 earnings call and investor briefing, featuring company executives including the CEO, CFO, and Chair. It details their presentations and investor meetings scheduled in Australia.MarketScreenerLumos Diagnostics Holdings Limited Stock (LDX)The provided text is a financial data profile for Lumos Diagnostics Holdings Limited rather than a narrative news article. It outlines the company's business in point-of-care diagnostic tests, lists projected financial figures, and notes an analyst consensus of "Buy" with a target price of 0.25 AUD. As there is no specific event or news development reported, a factual summary of events cannot be generated.MarketScreenerLumos Diagnostics Advances US Commercialization for Rapid Test; Shares Down 3%Lumos Diagnostics Holdings Limited, an Australian-based company, is advancing its US commercialization efforts for rapid diagnostic tests. The company's products, including FebriDx and ViraDx, target infectious diseases such as influenza and COVID-19.Seeking AlphaLumos Diagnostics Holdings Limited (LDXHF) Discusses Commercialisation Update and Market Strategy for FebriDx in the U.S. TranscriptLumos Diagnostics Holdings Limited discussed its commercialization update and market strategy for FebriDx in the U.S. during an investor briefing on June 10, 2026. The briefing involved company executives and partners, focusing on future plans and market positioning.